LXEO Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Zacks Investment Research

Wall Street Analysts Predict a 124.3% Upside in Lexeo Therapeutics, Inc. (LXEO): Here's What You Should Know

14 days ago - By: Lexeo Therapeutics

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

a month ago - By: Zacks Investment Research

Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High?

a month ago - By: Stocktwits

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In

a month ago - By: Stocktwits - Mentions: IWMW UWM

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process

a month ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering

a month ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

a month ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

a month ago - By: Benzinga - Mentions: SNWV CLRB APVO SPRB ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

a month ago - By: Benzinga - Mentions: NNE APP DGNX NAK ...

James Hardie Industries, AMD, Trilogy Metals, BTQ Technologies And Other Big Stocks Moving Higher On Tuesday

a month ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

3 months ago - By: The Motley Fool

Lexeo Reports Q2 Loss as Costs Jump 129%

3 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

4 months ago - By: Yahoo Finance - Mentions: MSFT HSBC EBAY UNH ...

Meta, Microsoft upgraded: Wall Street's top analyst calls

4 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

5 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

6 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

6 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

7 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

8 months ago - By: Lexeo Therapeutics

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

8 months ago - By: Stocktwits - Mentions: IWM VTI IBB

LEXEO THERAPEUTICS INC (LXEO) Stock News

LXEO Latest News, Press Relases and Analysis

Wall Street Analysts Predict a 124.3% Upside in Lexeo Therapeutics, Inc. (LXEO): Here's What You Should Know

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

Wall Street Analysts See a 108.23% Upside in Lexeo Therapeutics, Inc. (LXEO): Can the Stock Really Move This High?

Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In

Lexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval Process

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

12 Health Care Stocks Moving In Tuesday's Intraday Session

James Hardie Industries, AMD, Trilogy Metals, BTQ Technologies And Other Big Stocks Moving Higher On Tuesday

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Lexeo Reports Q2 Loss as Costs Jump 129%

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Meta, Microsoft upgraded: Wall Street's top analyst calls

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?